Investigational Drug Information for Esreboxetine
✉ Email this page to a colleague
What is the development status for investigational drug Esreboxetine?
Esreboxetine is an investigational drug.
There have been 4 clinical trials for Esreboxetine.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2009.
The most common disease conditions in clinical trials are Fibromyalgia, Myofascial Pain Syndromes, and [disabled in preview]. The leading clinical trial sponsors are Pfizer and [disabled in preview].
Summary for Esreboxetine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,665 |
| WIPO Patent Applications | 2,051 |
| Japanese Patent Applications | 253 |
| Clinical Trial Progress | Phase 2 (2009-05-01) |
| Vendors | 22 |
Recent Clinical Trials for Esreboxetine
| Title | Sponsor | Phase |
|---|---|---|
| Maintenance of Efficacy. | Pfizer | Phase 3 |
| Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine | Pfizer | Phase 1 |
| Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers | Pfizer | Phase 1 |
Clinical Trial Summary for Esreboxetine
Top disease conditions for Esreboxetine
Top clinical trial sponsors for Esreboxetine
US Patents for Esreboxetine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
